TW200423972A - Tablet having improved solubility - Google Patents

Tablet having improved solubility Download PDF

Info

Publication number
TW200423972A
TW200423972A TW093102449A TW93102449A TW200423972A TW 200423972 A TW200423972 A TW 200423972A TW 093102449 A TW093102449 A TW 093102449A TW 93102449 A TW93102449 A TW 93102449A TW 200423972 A TW200423972 A TW 200423972A
Authority
TW
Taiwan
Prior art keywords
weight
patent application
compound
tablet
starch
Prior art date
Application number
TW093102449A
Other languages
English (en)
Chinese (zh)
Inventor
Shuichi Matsuda
Hidekazu Syodai
Noboru Nagafuji
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of TW200423972A publication Critical patent/TW200423972A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW093102449A 2003-02-05 2004-02-04 Tablet having improved solubility TW200423972A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003027814 2003-02-05

Publications (1)

Publication Number Publication Date
TW200423972A true TW200423972A (en) 2004-11-16

Family

ID=32955433

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093102449A TW200423972A (en) 2003-02-05 2004-02-04 Tablet having improved solubility

Country Status (3)

Country Link
JP (1) JPWO2004078173A1 (ja)
TW (1) TW200423972A (ja)
WO (1) WO2004078173A1 (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080038344A1 (en) * 2004-10-01 2008-02-14 Nippon Zoki Pharmaceutical Co., Ltd. Solid Pharmaceutical Preparation
DK1884242T3 (da) * 2005-05-26 2013-05-06 Dainippon Sumitomo Pharma Co Farmaceutisk sammensætning omfattende lurasidon
WO2007114376A1 (ja) 2006-03-30 2007-10-11 Nippon Zoki Pharmaceutical Co., Ltd. 固形医薬製剤
EP2251012A4 (en) 2008-02-11 2013-03-06 Dainippon Sumitomo Pharma Co TABLET HAVING ENHANCED ELUTING PROPERTIES

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378848A (en) * 1992-02-12 1995-01-03 Shionogi & Co., Ltd. Condensed imidazopyridine derivatives
JP2000026282A (ja) * 1998-07-14 2000-01-25 Shionogi & Co Ltd 溶出性が改善された硬ゼラチンカプセル剤
BR0109643A (pt) * 2000-03-30 2003-04-22 Shionogi & Co Processo sintético e forma de cristal de derivados condensados da imidazopiridina

Also Published As

Publication number Publication date
JPWO2004078173A1 (ja) 2006-06-08
WO2004078173A1 (ja) 2004-09-16

Similar Documents

Publication Publication Date Title
ES2731601T3 (es) Composiciones de dosificación oral de liberación retardada que contienen CDDO-Me amorfo
TWI382838B (zh) 錠劑及其製造方法
US11279682B2 (en) Vortioxetine pyroglutamate
JP5714562B2 (ja) 経口用徐放性固形製剤
JP2013534242A (ja) ナルブフィンを含有する製剤及びそれらの使用
ES2319292T3 (es) Composicion medicinal solida estable, de administracion por via oral de ramosetron.
BR112021013675A2 (pt) Formulações de comprimido de liberação modificada que contêm inibidores de fosfodiesterase
WO2011102504A1 (ja) 経口用徐放性固形製剤
JP2022174317A (ja) 経口用医薬組成物及びその製造方法
TWI606826B (zh) 艾拉莫德或其鹽之用途
TWI382857B (zh) A pharmaceutical composition that improves the solubility of the oxazole compound to water
TW200423972A (en) Tablet having improved solubility
AU2021286284B2 (en) Antimicrobial compositions with effervescent agents
AU2018294561A1 (en) New oral formulations of belinostat
TW201607568A (zh) 包含１－［６－（嗎啉－４－基）嘧啶－４－基］－４－（１ｈ－１，２，３－三唑－１－基）－１ｈ－吡唑－５－醇鈉之醫藥劑型
JP2022027636A (ja) 安定化方法
JPWO2020246526A1 (ja) キサンチンオキシダーゼ阻害剤含有腸溶性製剤
BRPI0607372B1 (pt) Medicamento destinado à administração oral, compreendendo um inibidor da ciclooxigenase-2, e método de preparação do mesmo